Published in Medical Letter on the CDC and FDA, January 7th, 2007
While the issue of short-term efficacy and safety did not seem a big issue with the FDA panel, long-term safety was a matter of concern.
The disease affects some 60,000 children nationally. Celebrex is a member of the COX2 inhibitor class of drugs that include Vioxx and Bextra, both pulled from the market by the FDA because of serious or fatal heart-related injuries or stroke associated with the drug.
According to Howard Coleman, CEO and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.